Navigation Links
Robert W. Lee, Ph.D. Joins Particle Sciences as Vice President of Pharmaceutical Development
Date:4/28/2008

BETHLEHEM, Pa., April 28 /PRNewswire/ -- Particle Sciences, Inc. today announced the appointment of Robert W. Lee, Ph.D. to the position of Vice President, Pharmaceutical Development.

Dr. Lee joins Particle Sciences following more than 17 years experience in pharmaceutical research and development of both therapeutic drugs and diagnostic imaging agents. Most recently, he served Novavax, Inc. as Vice President of Pharmaceutical Development. Prior to that, Dr. Lee held senior management positions at Lyotropic Therapeutics, Inc. and IMCOR Pharmaceutical Co. Dr. Lee is currently serving as a scientific advisor for NanoScan Imaging, LLC, and Savara Pharmaceutical.

From 1990 to 2002, Dr. Lee held various R&D positions within Sterling Winthrop Pharmaceuticals Research Division, NanoSystems, and elan Drug Delivery, Inc. His areas of expertise include Preformulation, drug delivery, formulation development, analytical sciences, sterile manufacturing, and technology evaluation and development. Dr. Lee was one of the founding members of NanoSystems, a drug delivery company focused on the formulation of water-insoluble drugs. He maintains strong academic ties, including an appointment as Adjunct Associate Professor of Pharmaceutical Chemistry at the University of Kansas in 1992, and serving as a reviewer for both the International Journal of Pharmaceutics and Journal of Pharmaceutical Sciences.

Dr. Mitchnick comments that "Robert brings a wealth of experience to the Particle Sciences team. His background fits perfectly with our continued focus on advanced delivery systems. Particle Sciences typically deals with difficult to solubilize API's and nanotechnology based systems. Rob has deep experience in these areas as well as in clinical trial manufacturing, another area in which Particle sciences is expanding."

Dr. Lee received a Ph.D. in Physical Bioorganic Chemistry under the direction of Professor Thomas C. Bruice from the University of California, Santa Barbara and B.Sc.'s in both Chemistry and Biology from the University of Washington. He is the author or co-author of 11 patents, 14 provisional and PCT patent applications, nine research articles, and three book chapters.

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.

Contact:

Maureen Cochran

610-861-4701

mcochran@particlesciences.com


'/>"/>
SOURCE Particle Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Wyeth Chairman Robert Essner Announces June 27 Retirement
2. Genetic Engineering and Biotechnology News (GEN) Presents Exclusive Podcast with Robert Langer, Ph.D. on New Polymeric Drug Delivery Systems
3. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
4. Hiemstra Appoints Robert C. Glines as Director of Business Development
5. WellGen, Inc. Names Robert M. Hellauer as Chief Financial Officer
6. Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ... Major Weapon in the Battle Against Cancer
7. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
8. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
9. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
10. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
11. Immunotec Inc. announces retirement of President & CEO C.H. (Chuck) Roberts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 /PRNewswire/ - InMed Pharmaceuticals, Inc. ("InMed") (CSE: IN; OTCQB: ... February 24, 2017 a total of 10,672,750 common share purchase ... common share. Proceeds from the exercise of these warrants totalled ... ... are grateful for this expression of confidence by our warrant ...
(Date:2/27/2017)... YORK , February 27, 2017 ... by Stock-Callers.com for evaluation today, and they are: Anthera ... Pacific Biosciences of California Inc. (NASDAQ: PACB), and Conatus ... an article on ETF Trends, market observers are growing ... and administration could enact reforms to free cash held ...
(Date:2/27/2017)... FRANCISCO , Feb. 27, 2017 Fluxion ... Spain has been appointed as a ... System. The IsoFlux system will be used in Genetracer ... relevant to lung and colon cancer, with plans to ... The laboratory is utilizing Fluxion,s IsoFlux System to isolate, ...
(Date:2/27/2017)... ... February 27, 2017 , ... The Catalyst Midwest premix manufacturing facility ... offering premix services and private label organic services. , The first organic product is ... chief operating officer of Dynamite Marketing, which owns the facility. , Catalyst already has ...
Breaking Biology Technology:
(Date:2/7/2017)... February 7, 2017 Ipsidy Inc. ... Corporation [OTC: IDGS], ("Ipsidy" or the "Company") a provider ... processing services, is pleased to announce the following changes ... Effective January 31, 2017, Philip D. Beck ... CEO and President.  An experienced payment industry professional and ...
(Date:2/3/2017)... ANTONIO , Feb. 3, 2017  Texas Biomedical Research ... Dr. Larry Schlesinger as the Institute,s new ... Texas Biomed effective May 31, 2017. He is currently the ... Director of the Center for Microbial Interface Biology at Ohio ... Schlesinger as the new President and CEO of Texas Biomed," ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
Breaking Biology News(10 mins):